Evidence map›Paper›PMID 36048501›Full record

ArticleACS infectious diseases2022

Human Kinase IGF1R/IR Inhibitor Linsitinib Controls the In Vitro and Intracellular Growth of

Heng Wang, Jing Bi, Yuan Zhang, Miaomiao Pan, Qinglong Guo, Genhui Xiao, Yumeng Cui, Song Hu, Chi Kin Chan, Ying Yuan and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Heng WangGlobal Health Drug Discovery Institute, Haidian, Beijing 100192, China.
Jing BiNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen 518112, China.
Yuan ZhangGlobal Health Drug Discovery Institute, Haidian, Beijing 100192, China.
Miaomiao PanGlobal Health Drug Discovery Institute, Haidian, Beijing 100192, China.
Qinglong GuoNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen 518112, China.
Genhui XiaoGlobal Health Drug Discovery Institute, Haidian, Beijing 100192, China.
Yumeng CuiGlobal Health Drug Discovery Institute, Haidian, Beijing 100192, China.
Song HuGlobal Health Drug Discovery Institute, Haidian, Beijing 100192, China.
Chi Kin ChanGlobal Health Drug Discovery Institute, Haidian, Beijing 100192, China.
Ying YuanGlobal Health Drug Discovery Institute, Haidian, Beijing 100192, China.
Takushi KanekoGlobal Alliance for TB Drug Development, New York, New York 10005, United States.
Guoliang ZhangNational Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen 518112, China.
Shawn ChenGlobal Health Drug Discovery Institute, Haidian, Beijing 100192, China.ORCID 0000-0002-6678-3293
Beijing Haidian Hospital · CNSouthern University of Science and Technology · CNTB Alliance · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ATP provides energy in the biosynthesis of cellular metabolites as well as regulates protein functions through phosphorylation. Many ATP-dependent enzymes are antibacterial and anticancer targets including human kinases acted on by most of the successful drugs. In search of new chemotherapeutics for tuberculosis (TB), we screened repurposing compounds against the essential glutamine synthase (GlnA1) of

Indexed as

Mycobacterium tuberculosisTuberculosisAdenosine TriphosphateAnti-Bacterial AgentsGlutamineHumansImidazolesIsoniazidLipidsProtein Kinase InhibitorsPyrazinesReceptor, IGF Type 1TOR Serine-Threonine Kinases3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanolAdenosine TriphosphateAnti-Bacterial AgentsGlutamineIGF1R protein, humanImidazolesIsoniazidLipidsProtein Kinase InhibitorsPyrazinesReceptor, IGF Type 1TOR Serine-Threonine KinasesATP-dependent enzymeautophagyglutamine synthetaseIGF1R/IR inhibitorM. tuberculosis

Identifiers

PMID36048501
PMCPMC11807261
OpenAlexW4294001132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.